#ESMO2026 opened today in Madrid, and a big focus for EGFR+ #lungcancer is what happens when osimertinib stops working.
🔬 Here are 5 studies we’re watching, from new targeted combinations and antibody-drug conjugates to blood tests that could guide treatment decisions.
#LCSM
225 浏览 · 11 赞 · 3 转发 · 0 回复
FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)
https://esmocongress.esmo.orgPACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line
https://esmocongress.esmo.org来源：EGFR Positive Lung Cancer UK · x.com